Saxenda vs Mounjaro UK: Cost, Effectiveness & Which Is Better for Weight Loss

The most fundamental difference between Saxenda and Mounjaro lies in their pharmacological mechanisms — specifically, which hormonal pathways they activate.

Saxenda (liraglutide 3mg) — GLP-1 receptor agonist: - Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist — it mimics the GLP-1 hormone, which is naturally released after eating - GLP-1 acts on the brain (hypothalamus) to reduce appetite and increase satiety - Also slows gastric emptying (food leaves the stomach more slowly, prolonging fullness) - Stimulates insulin secretion in a glucose-dependent manner - Half-life of approximately 13 hours — necessitating daily injection

Mounjaro (tirzepatide) — Dual GIP/GLP-1 receptor agonist: - Mounjaro is a "twincretin" — the first medication to act as both a GLP-1 receptor agonist AND a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist simultaneously - The dual action provides greater overall hormonal signalling for appetite suppression and energy regulation than GLP-1 alone - GIP receptors are found in the hypothalamus (appetite regulation) and in adipose tissue (fat metabolism) - Half-life of approximately 5 days — allowing once-weekly dosing

Why dual action matters: The additional GIP agonism of tirzepatide appears to be responsible for its substantially greater weight loss efficacy compared to GLP-1-only agents. Some research suggests GIP and GLP-1 pathways interact synergistically in the hypothalamus, producing appetite suppression greater than the sum of either alone.

*This article is for educational purposes and does not constitute medical advice. Treatment decisions should be made with a qualified UK prescribing clinician.*

The clinical efficacy gap between Saxenda and Mounjaro is significant and represents one of the most important considerations when comparing these medications.

Saxenda (liraglutide 3mg) clinical trial data: - SCALE Obesity and Prediabetes trial (56 weeks): Average weight loss of 8.0% of body weight with liraglutide 3mg vs 2.6% with placebo - 63% of participants achieved ≥5% weight loss - 33% achieved ≥10% weight loss - Weight loss with Saxenda was a meaningful advance over orlistat (3–5%) and placebo at the time of its approval

Mounjaro (tirzepatide) clinical trial data — SURMOUNT-1: - Average weight loss of 20.9% (15mg dose) vs 2.4% placebo - 89% of participants at 15mg achieved ≥5% weight loss - 56% achieved ≥20% weight loss - Overall average across all doses: approximately 15–22% depending on dose achieved

Real-world comparison: For a UK patient weighing 100kg: - Saxenda: Expected loss of approximately 8kg over 56 weeks - Mounjaro (15mg): Expected loss of approximately 21kg over 72 weeks

Important nuance: - Direct head-to-head trials comparing liraglutide and tirzepatide specifically are limited — these comparisons are based on separate trial data - Individual response varies, and some patients respond particularly well to liraglutide - The SURMOUNT-5 trial directly compared tirzepatide and semaglutide (not liraglutide), confirming tirzepatide superiority to semaglutide

Beyond clinical efficacy, the dosing frequency difference between Saxenda and Mounjaro has significant practical implications for patient experience and treatment adherence.

Saxenda — daily injection: - Must be injected every day at approximately the same time - Pen device is used; injection sites: abdomen, thigh, or upper arm - Missed doses: If a dose is missed by more than 12 hours, skip and continue the next day (do not double dose) - Dose escalation schedule: 0.6mg/day for week 1, then 1.2mg, 1.8mg, 2.4mg, and finally 3mg — escalation over 5 weeks - Pen storage: Unopened pens stored in the fridge; in-use pens can be kept at room temperature (below 30°C) for up to 30 days

Mounjaro — weekly injection: - Injected once weekly on the same day each week - Pre-filled autoinjector pen; injection sites: abdomen, thigh, or upper arm - Missed doses: If missed by fewer than 4 days, inject as soon as possible; if more than 4 days, skip to next scheduled dose - Dose escalation: 2.5mg weekly for 4 weeks, then escalation by 2.5mg every 4 weeks up to a maximum of 15mg - Adherence advantage: Weekly dosing is consistently associated with better adherence in clinical studies and real-world data

Patient experience: Most patients transitioning from daily to weekly injections report a meaningful improvement in quality of life and reduced treatment burden. The pen devices for both medications are well-designed and needle-phobia is rarely a barrier once self-injection is learned.

*Practical guidance is based on UK prescribing information and patient experience data.*

Cost is a significant practical consideration for UK patients accessing either medication outside of NHS prescription.

Saxenda UK costs (approximate 2026 prices): - NHS: Saxenda is available via NHS Tier 3 weight management services in some areas, subject to local commissioning decisions. As a prescription medication, the standard NHS prescription charge applies (£9.90 per item as of 2026, or free with PPC/exemption). - Private prescription — Saxenda pen (6mg/mL, 3mL): Typically £90–£180 per month depending on dose and provider - 5 pens required per month at full 3mg dose (each pen delivers approximately 30 doses) - Annual private cost: Approximately £1,080–£2,160/year at maintenance dose

Mounjaro UK costs (approximate 2026 prices): - NHS: Available via NHS Tier 3 specialist weight management services (NICE TA924), subject to ICB commissioning and eligibility criteria - Private prescription — Mounjaro autoinjector (per month): - 2.5mg and 5mg doses: £130–£180/month - 10mg dose: £150–£220/month - 15mg dose: £180–£260/month - Annual private cost at 15mg: Approximately £2,160–£3,120/year

Value assessment: When cost-per-kg-lost is considered, Mounjaro's greater efficacy may deliver better value for money despite higher monthly costs — particularly for patients with substantial weight to lose. However, Saxenda's lower monthly cost makes it more accessible for patients who cannot afford the higher Mounjaro price point.

*All prices are approximate and subject to change. Check directly with UK registered pharmacies and prescribers for current pricing.*

Many UK patients currently on Saxenda are interested in switching to Mounjaro, particularly if their weight loss has plateaued or if they are aware of Mounjaro's superior efficacy data. This section outlines what is currently known about switching pathways.

Reasons UK patients consider switching: - Reached maximum Saxenda weight loss response and have plateaued - Desire for weekly rather than daily injection - Better affordability at some doses of Mounjaro - Clinician recommendation based on updated NICE guidance

How switching works clinically:

• •There is no mandatory washout period between liraglutide and tirzepatide — both work on GLP-1 pathways (tirzepatide additionally on GIP)
• •Standard practice is to stop Saxenda and begin Mounjaro at its starting dose (2.5mg) on the following injection day
• •Starting at the lowest Mounjaro dose allows tolerability to be established even in patients already accustomed to a GLP-1 agonist
• •Some patients already tolerant of GLP-1 effects may find the Mounjaro starting dose escalation period more comfortable than treatment-naive patients

What to discuss with your prescriber: - Document your Saxenda treatment history (dose achieved, weight lost, any side effects) - Provide current weight and BMI for reassessment - Confirm NHS or private prescribing pathway for Mounjaro - Discuss monitoring plan for the transition period

NHS switching: Patients accessing Saxenda through NHS Tier 3 services should discuss switching with their specialist team. The local pathway for transitioning to Mounjaro will vary by ICB.

*Switching decisions should always be made in consultation with your GMC-registered prescribing clinician. This article is for educational purposes only.*